491 related articles for article (PubMed ID: 29345296)
1. Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.
Maj E; Filip-Psurska B; Milczarek M; Psurski M; Kutner A; Wietrzyk J
Int J Oncol; 2018 Feb; 52(2):337-366. PubMed ID: 29345296
[TBL] [Abstract][Full Text] [Related]
2. The effect of combined treatment on head and neck human cancer cell lines with novel analogs of calcitriol and cytostatics.
Wietrzyk J; Milczarek M; Kutner A
Oncol Res; 2007; 16(11):517-25. PubMed ID: 18306931
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model.
Maj E; Filip-Psurska B; Świtalska M; Kutner A; Wietrzyk J
Int J Mol Sci; 2015 Nov; 16(11):27191-207. PubMed ID: 26580599
[TBL] [Abstract][Full Text] [Related]
4. Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts.
Wang D; Jiang Z; Zhang L
Med Oncol; 2012 Jun; 29(2):600-6. PubMed ID: 21455800
[TBL] [Abstract][Full Text] [Related]
5. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model.
Jørgensen A; Blomberg Jensen M; Nielsen JE; Juul A; Rajpert-De Meyts E
J Steroid Biochem Mol Biol; 2013 Jul; 136():238-46. PubMed ID: 23098692
[TBL] [Abstract][Full Text] [Related]
6. Dendrobine targeting JNK stress signaling to sensitize chemotoxicity of cisplatin against non-small cell lung cancer cells in vitro and in vivo.
Song TH; Chen XX; Lee CK; Sze SC; Feng YB; Yang ZJ; Chen HY; Li ST; Zhang LY; Wei G; Shi J; Xu K; Ng TB; Zhu LL; Zhang KY
Phytomedicine; 2019 Feb; 53():18-27. PubMed ID: 30668397
[TBL] [Abstract][Full Text] [Related]
7. MART-10, the new brand of 1α,25(OH)2D3 analog, is a potent anti-angiogenic agent in vivo and in vitro.
Chiang KC; Sun CC; Chen MH; Huang CY; Hsu JT; Yeh TS; Chen LW; Kuo SF; Juang HH; Takano M; Kittaka A; Chen TC; Yeh CN; Pang JH
J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):26-34. PubMed ID: 26385607
[TBL] [Abstract][Full Text] [Related]
8. Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.
Pan F; Tian J; Zhang X; Zhang Y; Pan Y
J Cancer Res Clin Oncol; 2011 Sep; 137(9):1397-408. PubMed ID: 21796416
[TBL] [Abstract][Full Text] [Related]
9. Correlation between VDR expression and antiproliferative activity of vitamin D3 compounds in combination with cytostatics.
Pelczynska M; Wietrzyk J; Jaroszewicz I; Nevozhay D; Switalska M; Kutner A; Zabel M; Opolski A
Anticancer Res; 2005; 25(3B):2235-40. PubMed ID: 16158969
[TBL] [Abstract][Full Text] [Related]
10. Dihydroberberine exhibits synergistic effects with sunitinib on NSCLC NCI-H460 cells by repressing MAP kinase pathways and inflammatory mediators.
Dai B; Ma Y; Wang W; Zhan Y; Zhang D; Liu R; Zhang Y
J Cell Mol Med; 2017 Oct; 21(10):2573-2585. PubMed ID: 28444871
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
Tang N; Zhang Q; Fang S; Han X; Wang Z
Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
Hui EP; Lui VW; Wong CS; Ma BB; Lau CP; Cheung CS; Ho K; Cheng SH; Ng MH; Chan AT
Invest New Drugs; 2011 Dec; 29(6):1123-31. PubMed ID: 20467883
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
[TBL] [Abstract][Full Text] [Related]
14. Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer.
Li X; Tong LJ; Ding J; Meng LH
Cancer Lett; 2014 Jan; 342(1):159-66. PubMed ID: 24018642
[TBL] [Abstract][Full Text] [Related]
15. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.
Coxon A; Ziegler B; Kaufman S; Xu M; Wang H; Weishuhn D; Schmidt J; Sweet H; Starnes C; Saffran D; Polverino A
Mol Cancer; 2012 Sep; 11():70. PubMed ID: 22992329
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative activity of vitamin D compounds in combination with cytostatics.
Pelczynska M; Switalska M; Maciejewska M; Jaroszewicz I; Kutner A; Opolski A
Anticancer Res; 2006; 26(4A):2701-5. PubMed ID: 16886680
[TBL] [Abstract][Full Text] [Related]
18. Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations.
Bao YX; Zhao XD; Deng HB; Lu CL; Guo Y; Lu X; Deng LL
Cell Oncol (Dordr); 2016 Aug; 39(4):343-52. PubMed ID: 27016208
[TBL] [Abstract][Full Text] [Related]
19. Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice.
Li JY; Ren YP; Yuan Y; Ji SM; Zhou SP; Wang LJ; Mou ZZ; Li L; Lu W; Zhou TY
Acta Pharmacol Sin; 2016 Jul; 37(7):930-40. PubMed ID: 27180983
[TBL] [Abstract][Full Text] [Related]
20. Enhanced anticancer effects of Scutellaria barbata D. Don in combination with traditional Chinese medicine components on non-small cell lung cancer cells.
Wang Q; Acharya N; Liu Z; Zhou X; Cromie M; Zhu J; Gao W
J Ethnopharmacol; 2018 May; 217():140-151. PubMed ID: 29458146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
